Cargando…
Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar(®) in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
BACKGROUND: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®,...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Tehran University of Medical Sciences
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174042/ https://www.ncbi.nlm.nih.gov/pubmed/30320008 |